Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer’s disease: insights from experimental and computational approaches Authors: Mojnu Mia, Amit Dutta, Md Mainuddin Hossain, Juthi Adhikari, Md Masuder Rahman, Abu Zaffar Shibly Published: 2026 ABSTRACT Graphical abstractUnlabelled ImageKeywords: Alzheimer’sdisease, Caenorhabditis elegans, Ganoderma lucidum, Neuroprotection, Antioxidant activity Introduction Alzheimer’s disease (AD) is the most prevalent form of age-related dementia, characterized by progressive memory loss, cognitive dysfunction, and behavioral impairment.1 Amyloid-β (Aβ) plaques deposited extracellularly, hyperphosphorylated tau accumulated intracellularly, synaptic degeneration, and extensive neuronal loss are the neuropathological features of AD.2 Aβ, particularly in its oligomeric form, is highly neurotoxic and plays a central role in triggering downstream pathological cascades, including oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis.3 Metal ions such as iron (Fe), copper (Cu), zinc (Zn), and aluminum (Al) play a crucial role in the aggregation of amyloid-β (Aβ) monomers into oligomeric and fibrillar assemblies. These transition metals bind directly to histidine residues within the Aβ peptide, altering its conformation and facilitating β-sheet formation, which accelerates nucleation and aggregation.4, 5 Metal coordination can stabilize intermediate oligomeric species, increasing the population of soluble Aβ oligomers that are neurotoxic.6 Both Fe3⁺ and Cu2⁺ ions have been shown to catalyze Aβ aggregation in vitro and in vivo, and chelation of these ions can reverse or slow fibrillization.7 In addition to promoting aggregation, redox-active metals such as Fe and Cu generate ROS through Fenton and Haber–Weiss chemistry when bound to Aβ, producing hydrogen peroxide and hydroxyl radicals.8, 9 These ROS contribute to neuronal damage and synaptic dysfunction by oxidatively damaging lipids, proteins, and nucleic acids. Iron accumulation near amyloid plaques has been shown to enhance Aβ aggregation and oxidative stress, while Cu–Aβ and Fe–Aβ complexes facilitate redox cycling, exacerbating neurotoxicity.10, 11, 12 Collectively, dysregulated metal homeostasis promotes a feedback loop of Aβ aggregation, ROS generation, and neuronal degeneration in Alzheimer’s disease. Despite decades of research, current AD therapies, including cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, provide only temporary symptomatic relief without halting neurodegeneration. Although recently approved anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab offer modest disease-modifying benefits, their clinical use is limited by restricted efficacy, high cost, and risks of amyloid-related imaging abnormalities (ARIA), highlighting the need for more effective multi-target therapeutic strategies.13, 14, 15 In this context, Ganoderma lucidum (G. lucidum), a well-known medicinal mushroom used in traditional East Asian medicine, has emerged as a promising candidate.16 Historically referred to as “Lingzhi,” G. lucidum has been widely used for enhancing health and longevity, and pharmacological studies have demonstrated its therapeutic potential in managing inflammation, diabetes, cancer, cardiovascular disorders, and neurodegenerative diseases.17, 18 The neuroprotective activity of G. lucidum is primarily attributed to its rich repertoire of bioactive components, including triterpenoids, polysaccharides, phenolic compounds, and sterols, which are known to exhibit antioxidant, anti-inflammatory, and anti-apoptotic effects.19 Oxidative stress caused by an excessive accumulation of ROS, is a key contributor to the pathogenesis of AD.3, 20 These ROS are exacerbated by Aβ aggregation and mitochondrial dysfunction, promoting neuronal damage and cognitive decline.21 Therefore, targeting oxidative stress alongside Aβ production offers a rational strategy for AD therapy. The nematode Caenorhabditis elegans (C. elegans) has been increasingly utilized as an in vivo model for studying AD due to its short lifespan, well-characterized genome, and availability of transgenic strains expressing human Aβ.22 Importantly, C. elegans lacks endogenous Aβ production, enabling the direct observation of Aβ-induced pathologies such as paralysis, making it an ideal system for evaluating neuroprotective and anti-amyloid compounds.23 In addition to in vivo validation, computational approaches such as molecular docking, molecular dynamics (MD) simulation, and ADMET profiling have become integral to early-stage drug discovery. While molecular docking predicts the preferred binding orientation of ligands toward a target protein, MD simulation provides further insight into the dynamic stability and conformational behavior of protein–ligand complexes under near-physiological conditions. Aβ accumulation is a central driver of AD, and its inhibition represents a validated therapeutic strategy.24 Docking compounds against Aβ can help identify potential inhibitors that can prevent Aβ accumulation as well as AD pathogenesis. disrupt Aβ production at the enzymatic level. In light of these considerations, the present study aimed to evaluate the neuroprotective and anti-Alzheimer’s potential of G. lucidum methanolic extract using C. elegans models and integrated in silico analyses. The extract was assessed for antioxidant activity, protection against paraquat-induced oxidative stress, and mitigation of Aβ-induced paralysis. In parallel, selected G. lucidum-derived compounds were screened against Aβ through molecular docking and ADMET profiling, followed by MD simulation of the top-ranked protein–ligand complexes to evaluate their structural stability and dynamic behavior under near-physiological conditions. This integrated experimental–computational approach provides a robust framework for identifying multi-target neuroprotective candidates from G. lucidum and supports their potential development as anti-Alzheimer’s interventions targeting multiple pathological features of AD. Materials and methods DPPH assay The total antioxidant capacity of G. lucidum was assessed using the DPPH radical scavenging assay, which evaluates the ability of antioxidant compounds to reduce the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH). Methanolic extracts of G. lucidum were prepared at different concentrations (2.5–150 µg/mL), and 1000 µL of each concentration was mixed with 3 mL of DPPH solution (8 mg/100 mL in methanol). Similarly, varying concentrations of ascorbic acid were used as a positive control. The reaction mixtures were incubated in the dark for 30 min to allow the reaction to occur. Subsequently, the decrease in absorbance was measured at 517 nm using a BioTek ELX800 Absorbance Microplate Reader (Winooski, VT, USA). The antioxidant activity was expressed as the percentage of DPPH radical inhibition, representing the free-radical scavenging capacity of the samples, calculated using the following equation: where A0 denotes the absorbance of the DPPH solution prepared in methanol (control), whereas A1 represents the absorbance of the reaction mixture containing the G. lucidum extract. The IC50 value of the G. lucidum extract was determined using linear regression analysis, plots where the abscissa represented the concentration of tested G. lucidum extract and the ordinate the average percent of antioxidant activity from three separate tests. Preparation of NGM To prepare solid NGM, 3 g of NaCl, 2.5 g of peptone, and 20 g of agar were dissolved in water and the volume was adjusted to 1 L. The mixture was then autoclaved for 1 h and subsequently cooled for 1 h in a 55 °C water bath. After cooling, supplements were added sequentially with mixing after each addition, including 1 mL of cholesterol (5 mg/mL in ethanol), 1 mL of 1 M CaCl2, 1 mL of 1 M MgSO4, and 25 mL of 1 M KPO4 buffer (pH 6.0). The medium was dispensed into sterile Petri plates using an automated plate pourer equipped with a peristaltic pump, ensuring sterile handling throughout the process. The prepared NGM plates were stored at 4 °C until use and were brought to room temperature prior to introducing the worms. Nematode synchronization All experiments were conducted using age-synchronized populations of C. elegans, which were cultured on standard NGM plates until reaching the L4 larval stage. Synchronized cohorts were generated using a bleaching protocol (4 M NaOH: bleach: water = 1:2:7). Briefly, gravid adult hermaphrodites were collected and washed in a 50 mL Falcon tube with M9 buffer (composed of 5.8 g Na2HPO4, 3.0 g KH2PO4, 0.5 g NaCl, and 1.0 g NH4Cl dissolved in 1 L of ddH2O). The worm suspension containing embryos was then treated with the bleaching solution to isolate the embryos. Following bleaching, the embryos were washed three times with M9 buffer to remove residual chemicals. The recovered embryos were subsequently transferred to NGM plates without a food source and incubated for approximately 18 h to allow hatching and synchronization at the L1 larval stage. The synchronized L1 larvae were then collected, transferred onto NGM plates seeded with actively growing OP50-1 bacteria, and allowed to develop until reaching the L4 stage. Worms at the L4 stage were subsequently utilized for all downstream experiments. Extract preparation Fruiting body (non-toxic) part of G. lucidum Powder (200 gm) was purchased from PharmaBD (https://pharmabd.shop/). In a plastic bottle, the powder and ethanol were diluted at a 1:20 ratio. The mixture was then left in the room to fully mix for 7 days. Within these days, the mixture was being shaken repeatedly. After being fully mixed, the liquid was separated from the mixture using Watman filter paper using a vacuum pump. A rotary evaporator was used to evaporate ethanol from the liquid, and the extract was dried in laminar airflow. The extract was stored in a 4 °C fridge for further study. The extract was prepared as a single batch using ethanol as the solvent system to minimize variability. From 200 gm of starting material 10 gm of dried extract was obtained, corresponding to an extraction yield of 5% (w/w). Stock solution preparation for both in vitro and in vivo Two stock solutions were prepared: 20 mg/mL ethanol for the DPPH and paralysis assays, and 20 mg/mL DMSO for the paralysis assay. In a Falcon tube, 300 mg of G. lucidum extract was measured and diluted with 15 mL of ethanol. To prepare DMSO stock, the same amount of G. lucidum was diluted in 15 mL of DMSO in a Falcon tube. To ensure proper mixing, the mixture was repeatedly vortexed. Strain maintenance The C. elegans strains employed in this study were Bristol N2 (wild-type), CL4176 (dvIs27 [myo-3p::A-Beta (1–42)::let-851 (3′UTR) + rol-6(su1006)]). All nematodes were obtained from the Caenorhabditis Genetics Center (CGC, University of Minnesota, MN, USA). All nematodes used in this study were cultured on NGM agar coated with E. coli OP50. CL4176, mtl-2::GFP, and snb-1::Abeta 1–42; mtl-2::GFP nematodes were cultured at 16 °C, whereas N2 was routinely maintained at 20 °C. To obtain age-synchronized populations, an appropriate number of gravid adult nematodes were placed on fresh NGM mediums for 2 h to lay eggs. Then, gravid adult nematodes were transferred away, whereas synchronized eggs were left on the plates for further experiments.25 A total of 100 worms (N2 and CL4176) were used per condition with three independent biological replicates for paralysis assay. For oxidative stress assay 200 worms were used per condition with three independent biological replicates. Worms were randomly allocated to experimental groups to minimize bias. Oxidative stress assay An acute oxidative stress assay was conducted with minor modifications to previously reported methods. Approximately 200 synchronized L1-stage worms of C. elegans were cultured on 9 cm NGM plates either in the absence or presence of G. lucidum extract at concentrations of 0.5 g/mL, 1.5 g/mL, and 4.5 g/mL, and maintained at 20 °C until they reached the L4 larval stage. Subsequently, the worms were collected by washing the plates with M9 buffer, and approximately 20 worms were transferred into each well of a 24-well plate containing 50 mM Paraquat dissolved in double deionized water (ddH2O). The worms were exposed to paraquat for 6 h to induce oxidative stress. During the treatment period, the plate lids were opened at 1-hour intervals to ensure adequate oxygen supply. After 6 h of exposure, the survival rate of worms in each treatment group was determined and expressed as a percentage. Amyloid-β paralysis assay A paralysis assay was conducted using the transgenic strain C. elegans CL4176, which conditionally expresses the human Aβ1–42 peptide in muscle cells. The worms were age-synchronized and incubated from the embryonic stage for 48 h at 16 °C on NGM plates containing different concentrations of G. lucidum extract (0.5 g/mL, 1.5 g/mL, and 4.5 g/mL). To induce Aβ-mediated paralysis, the temperature was subsequently shifted from 16 °C to 25 °C. Paralysis assessment began 20 h after the temperature upshift and was recorded at 3 h intervals until 32 h. Worms that exhibited only head movement without producing a full body wave in response to gentle touch stimulation were classified as paralyzed. Each experimental condition was performed in triplicate, with at least 60 nematodes included per group. The results were expressed as the percentage (%) of non-paralyzed worms. Statistical analysis All data are presented as mean ± standard error of the mean (SEM). Statistical analyses were performed using IBM SPSS Statistics 24 (IBM Corp., Chicago, IL, USA), and graphical representations were generated using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). Comparisons between two groups were conducted using an unpaired two-tailed t-test. For comparisons involving multiple groups, a one-way analysis of variance (ANOVA) was applied, followed by Dunnett’s post hoc test to determine pairwise statistical significance relative to the control group.26 In-silico analysis G. lucidum phytochemical retrieval G. lucidum compounds was searched in Medicinal Fungi Secondary Metabolite and Therapeutics (MeFSAT) is a database27 (https://cb.imsc.res.in/mefsat/home) and 276 compounds were retrieved. The MeFSAT database was selected as the primary source for ligand library preparation because it is a manually curated and literature-derived repository specifically focused on secondary metabolites of medicinal fungi, providing high-confidence structural and biological annotation of natural products relevant to our study. Unlike general or partially curated databases, MeFSAT integrates compounds collected through extensive published literature mining and manual curation, ensuring reliability of chemical structures and associated annotations for computational screening purposes. Importantly, MeFSAT compiles 1830 non-redundant secondary metabolites with validated chemical structures and physicochemical properties, making it a robust and widely used resource in natural product-based in silico drug discovery studies. After manual curation for canonical SMILES and PubChem CID for each phytochemical, 250 compounds were screened for further analysis. Drug likeliness and ADME properties prediction G. lucidum compounds were analyzed for drug-likeness and ADME properties through the SWISS-ADME and pkCSM web servers.28, 29 SWISS-ADME was employed for ADMET profiling due to its robustness, reliability, and widespread use in early-stage drug discovery for evaluating key pharmacokinetic and drug-likeness properties, including GI absorption, BBB permeability, CYP inhibition, and toxicity-related parameters. Its well-validated and reproducible framework makes it a standard tool for preliminary in silico screening, ensuring comparability with previously published studies. Lipinski’s “Rule of Five” is a widely recognized guideline used to evaluate the likelihood of a compound being well absorbed orally. According to this rule, a molecule is considered to have favorable oral bioavailability if it meets the following criteria: a molecular weight (MW) below 500 Daltons (Da), an octanol–water partition coefficient (iLOGP) less than 5, fewer than 5 hydrogen bond donors, and fewer than 10 hydrogen bond acceptors. According to the lipinski's rule of five, compounds predicted to be orally bioavailable should satisfy specific physicochemical criteria. Molecules that violate two or more of these parameters are generally considered unlikely to possess adequate oral bioavailability and are therefore excluded from further analysis in the study. ADME analysis is essential for evaluating the pharmacokinetic and pharmacodynamic properties of a candidate compound intended for therapeutic use. The compounds that were able to penetrate BBB barrier were selected for the further analysis. Major ADME characteristics were absorption (water solubility, human GI absorption and P-gp substrate), metabolism (CYP2D6 and CYP3A4 inhibitor), excretion (drug total clearance) and toxicity (AMES toxicity, hERG channel inhibitors). Toxicity prediction Toxicological prediction is an essential step for evaluating the potential tolerability of chemical compounds prior to their application in human or animal models. Currently, computational approaches provide efficient tools for assessing the safety profile of candidate substances, enabling the estimation and quantification of potential toxic effects. Screened compound from drug-likeness and ADME analysis were subjected for toxicity analysis. To assess the potential toxicological effects of the compounds, the pkCSM and Protox-III web servers29, 30 were employed. AMES toxicity, hERG channel inhibition, hepatotoxicity, and other toxicity-related endpoints were predicted using the pkCSM. Protox-III predicts various toxicity endpoints for a given chemical, including neurotoxicity, hepatotoxicity, carcinogenicity, and mutagenicity. Protein retrieval and preparation The protein structure of Aβ (Protein Fibril) was obtained from the RCSB protein database31 (https://www.rcsb.org/) with Conformers Calculated: 100, Conformers Submitted: 10, and Selection Criteria: target function (PDB Id: 6SZF). Numerous experimental protein and nucleic acid structures are present in the protein database. Once the protein was retrieved, it was prepared for additional processing using Discovery Studio 2020,32 which eliminated the protein's original ligand, co-factors, water molecules, and metal ions. Energy minimization was performed to stabilize the protein structures, and the SWISS-PDB Viewer (version 4.1.0) was utilized using the GROMOS96 43B1 force field to obtain energetically favorable conformations prior to downstream analysis.33 Preparation of screened compounds Energy minimization of the screened compounds was performed using the MMFF94 (Merck Molecular Force Field 94) implemented in SWISS-PDB Viewer (version 4.1.0).34 This force field is widely applied for the optimization of small organic molecules, including natural products, due to its reliable parameterization of diverse chemical structures. The minimization step was carried out to remove steric clashes and obtain energetically stable ligand conformations prior to molecular docking analysis. Metal binding sites prediction of Aβ For the purpose of predicted metal ion binding sites, we utilized Metal Ion-Binding (MIB2) server35 (https://combio.life.nctu.edu.tw/MIB2/). MIB2 employs both the (PS)2 method and the AlphaFold Protein Structure Database to generate predicted protein structures, which are subsequently used for metal ion docking and binding residue prediction. Compared to its predecessor, MIB, the updated MIB2 framework demonstrates significant advancements by incorporating a larger set of MIB residue templates and implementing a metal ion type-specific scoring function. Furthermore, MIB2 extends its predictive capability to a total of 18 different metal ion types, thereby enhancing the accuracy and scope of binding site prediction. Molecular docking and G. lucidum-Aβ interaction profiling In the present study, blind molecular docking was performed using PyRx software36 to evaluate the optimal binding orientations, conformational states, and interaction energies of selected G. lucidum-derived compounds toward Aβ. Ligand structures were prepared and converted into PDBQT format using Open Babel software to generate docking-compatible inputs for AutoDock Vina. A grid box encompassing the entire Aβ structure was defined to enable unbiased exploration of all possible ligand-binding regions across the protein surface, allowing identification of potential interaction sites without prior restriction to a specific active site. This blind docking strategy was adopted to avoid bias toward predefined binding pockets and is particularly suitable for Aβ, which is a flexible, aggregation-prone peptide lacking a single well-characterized or experimentally validated active site and instead exhibits multiple potential interaction interfaces. Therefore, active site prediction tools such as CASTp or PrankWeb were not employed, as the study design focused on global interaction screening rather than site-specific docking. The docking results were visualized and analyzed using PyMOL Molecular Graphics System (version 2.0) and BIOVIA Discovery Studio Client 2020 to examine non-bonded interactions and binding conformations of the compound–Aβ complexes. Upon completion of the docking simulations, the conformation exhibiting the lowest binding energy (i.e., the most negative docking score) was selected as the optimal binding pose for each compound–Aβ complex. Molecular dynamic simulation A 100-nanosecond (ns) molecular dynamics (MD) simulation was performed to investigate the binding stability of Aβ in complex with 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A. The simulations were carried out in a Linux environment using Maestro 2020.4 with the OPLS4 force field. The OPLS4 force field was employed as it offers an updated and highly accurate parameterization for both proteins and small molecules, with improved treatment of torsional profiles and non-bonded interactions, making it particularly suitable for protein–ligand complex stability assessment in drug discovery studies. The objective of these simulations was to investigate the dynamic behavior and structural stability of the protein–ligand complexes over the course of the simulation.37 The system was solvated using the TIP3P water model within an orthorhombic periodic boundary box. The TIP3P water model was selected for MD simulations due to its wide adoption, computational efficiency, and proven compatibility with the OPLS4 force field, which together ensure stable and reliable solvation behavior in biomolecular systems. Compared to alternative models such as SPC, TIP3P is more commonly parameterized alongside modern protein force fields and provides improved consistency in reproducing protein–ligand interaction dynamics within the OPLS framework. To achieve charge neutrality and mimic physiological ionic conditions, Na⁺ and Cl⁻ ions were added at a concentration of 0.15 M. Prior to the production run, the solvated protein–ligand complex underwent a 100-ps energy minimization to relieve steric clashes and unfavorable contacts in the initial configuration. Equilibration was considered complete when the maximum force fell below 1000 kJ·mol⁻1·nm⁻1. All bonds involving hydrogen atoms were constrained using the SHAKE algorithm, which facilitated gradual system heating to 300 K.38 The application of SHAKE allowed for the use of larger integration time steps, thereby enhancing computational efficiency while maintaining the stability of the simulation. By constraining high-frequency bond vibrations, this method preserves the stability of the simulation while retaining the overall dynamic behavior of the system.39 Trajectory snapshots were recorded at 100-ps intervals throughout the simulation. The stability of the protein–ligand complexes—Aβ bound to 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A—was assessed by analyzing key structural and dynamic parameters, including the root mean square deviation (RMSD)40 and root mean square fluctuation (RMSF).41 Binding free energy calculation (MMGBSA) The binding free energies (ΔG_bind) of the protein–ligand complexes were calculated using the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method implemented in the Schrödinger Maestro suite (Prime module).42 Representative snapshots extracted from the equilibrated MD trajectories were used for energy estimation. The MM/GBSA approach combines molecular mechanics energies (bonded, electrostatic, and van der Waals terms) with an implicit solvent model (VSGB) to estimate the relative binding free energy of complexes. This method is widely used for post-docking refinement and comparative ranking of ligand binding affinities in structure-based drug design studies. The binding free energy (ΔG_bind) was computed as: where each energy term includes molecular mechanics energy and solvation contributions. This approach provides a reliable and computationally efficient estimation of relative binding strengths for protein–ligand complexes. Results DPPH radical scavenging activity In this study, he methanolic extract of G. lucidum demonstrated significant antioxidant activity, as evidenced by its dose-dependent scavenging of 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals (Fig. 1). The antioxidant potency was quantified using the IC50 value, representing the concentration of extract required to inhibit 50% of DPPH radical activity. This value was determined through a linear regression analysis of the percentage inhibition against extract concentration, with absorbance measured at 517 nm. DPPH radical scavenging activity of G. lucidum extract (A) and ascorbic acid (B) Percent inhibition was measured across concentrations. Linear regression lines were used to estimate IC50 values. The G. lucidum extract achieved a maximum DPPH radical scavenging activity of 96% at 125 µg/mL. The calculated IC50 value for the extract was 13.47 µg/mL, indicating a strong antioxidant effect (Fig. 1A). In comparison, the standard antioxidant ascorbic acid showed an IC50 of 8.08 µg/mL (Fig. 1B). Based on antioxidant strength classifications: very strong (IC50 < 50 µg/mL), strong (50–100 µg/mL), moderate (101–150 µg/mL), and weak (250–500 µg/mL), the G. lucidum extract falls within the very strong category.43 These findings highlight the potent radical-scavenging potential of G. lucidum, comparable to that of established synthetic antioxidants. G. lucidum extract exhibit neuroprotective effect by countering oxidative stress The protective effect of G. lucidum extract against oxidative stress was evaluated using C. elegans. The worms were exposed to oxidative conditions by using paraquat, and their survival rates were assessed across different treatment concentrations (0.5, 1.5, and 4.5 mg/mL), with DMSO serving as the control. The Fig. 2 showed that treatment with 0.5 mg/mL of G. lucidum extract resulted in a substantial increase in survival, reaching an average of 80.79%. This improvement was statistically significant (p < 0.01) compared to the control, suggesting that this concentration provides strong protection against oxidative damage. Effect of G. lucidum treatment on oxidative stress resistance in N2 strain. 0.5 mg/ml and 1.5 mg/ml of G. lucidum-treated C. elegans show a significantly increased survival rate compared to the control (P** < 0.001 and P* 0<.01, respectively). At a moderate concentration of 1.5 mg/mL, the survival rate decreased to 65.44%, which is still significantly higher than that of the control group (p < 0.05), but less effective than the 0.5 mg/mL treatment. Interestingly, the highest tested concentration of 4.5 mg/mL did not exhibit any additional protective effect, with the survival rate averaging 55.83%, which was nearly identical to that of the control. This lack of improvement, despite a higher dose, suggests a potential saturation effect at elevated concentrations. Paralysis assay The neuroprotective potential of G. lucidum was further validated using a DMSO-induced paralysis assay in C. elegans. The control group exhibited rapid paralysis, with 94% immobility by 56 h. Treatment with 0.5 mg/mL significantly delayed paralysis, with 65.79% motility at 59 h and 35.75% at 62 h, compared to 31.03% and 15% in controls, respectively. The highest dose (4.5 mg/mL) showed reduced efficacy, with only 16.58% survival at 62 h, suggesting possible cytotoxicity. At a concentration of 1.5 mg/mL, the treatment maintained 61.42% motility at 59 h and 21.91% at 62 h (Fig. 3). These findings confirm a dose-dependent neuroprotective effect, with 0.5 mg/mL providing the most consistent protection, while higher doses may compromise efficacy. Effect of G. lucidum extract treatment on paralysis in C. elegans CL4176 Strain. In- silico analysis Drug likeliness properties of G. lucidum-derived phytochemicals The process of drug development is both costly and time-intensive. Computational approaches now facilitate the early prediction of key properties that determine a compound’s therapeutic potential.44 Relevant drug-likeness parameters typically include the calculated partition coefficient (iLogP), aqueous solubility, molecular weight (MW), and the topological polar surface area (TPSA), among others. G. lucidum phytochemicals were screened for drug likeliness properties and 213 compounds showed maximum 1 Lipinski’s rule violation. Other compounds were ruled out as it showed 2 or more violations as it will be non-orally bioavailable drug (Table S1). ADME profiling and toxicity test PKCSM and SWISS-ADME provide ADME information for the G. lucidum phytochemicals. Among 213 phytochemicals, 162 showed Blood brain barrier penetration which is an important parameter for Alzheimer’s drug. After considering parameters like intestinal absorption, P-gp inhibitor, CYP enzyme inhibitor, hERG blocker and excretion, 15 phytochemicals were selected for further analysis. Drug likeliness properties of these 15 phytochemicals are given in Table 1. All the phytochemicals showed high confidence (***) in intestinal absorption (Table 2). None of the phytochemicals were P-gp substrate though Epoxyganoderiol (A, B and C) showed higher and Ganoderiol A exhibited moderate inhibition to P-glycoprotein. The cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, represent two of the primary hepatic systems responsible for drug metabolism. The results indicate that none of the tested compounds are predicted to inhibit these key enzymes. Table 1Drug-likeness profile of G. lucidum- derived phytochemicals.PhytochemicalsMWRotatable bondsH-bond acceptorsH-bond donorsTPSAiLOGPLipinski violations(+)-Epogymnolactam171.1933261.861.490Alpha-Terpineol154.2511120.232.5103,7-Dimethylocta-1,6-dien-3-ol(linalool)154.2541120.232.70Epoxyganoderiol A472.754270.064.411Epoxyganoderiol B454.6853149.834.451Epoxyganoderiol C456.753252.994.6815,6-Dihydroergosterol398.6641120.234.771Ganoderal A436.6752034.144.151Ganoderal B454.6853154.374.131Ganoderic aldehyde A454.6853154.374.31Ganoderic aldehyde TR452.6753154.374.231Ganoderiol A474.7264480.924.381Ganoderlactone E472.57172117.972.440Lovastatin404.5475172.833.940Lucidumol A472.754274.64.190Ganodermic acid JB470.6854377.763.961 Drug-likeness profile of G. lucidum- derived phytochemicals. Table 2ADME profile of G. lucidum- derived phytochemicals.PhytochemicalsIntestinal AbsorptionP-gp InhibitorP-gp SubstrateBBBCYP 2D6 InhibitorCYP 3A4 InhibitorhERG Blockers(+)-EpogymnolactamA***NI ***NS **P ***NI ***NI ***Safe ***Alpha-TerpineolA ***NI ***NS ***P ***NI ***NI ***Safe ***3,7-Dimethylocta-1,6-dien-3-ol(linalool)A ***NI ***NS ***P ***NI ***NI ***Safe ***Epoxyganoderiol AA ***I ***NS *P ***NI ***NI ***Safe ***Epoxyganoderiol BA ***I ***NS **P ***NI ***NI ***Safe ***Epoxyganoderiol CA ***I ***NS *P ***NI ***NI ***Safe ***5,6-DihydroergosterolA ***NI ***NS **P ***NI ***NI ***Safe ***Ganoderal AA ***NI ***NS **P ***NI ***NI ***Safe ***Ganoderal BA ***NI ***NS **P ***NI ***NI ***Safe ***Ganoderic aldehyde AA ***NI ***NS **P ***NI ***NI ***Safe ***Ganoderic aldehyde TRA ***NI ***NS **P ***NI ***NI ***Safe ***Ganoderiol AA ***I **NS *P ***NI ***NI ***Safe ***Ganoderol BA ***NI ***NS **P ***NI ***NI ***Safe ***Lucialdehyde AA ***NI ***NS **P ***NI ***NI ***Safe ***Lucidumol BA ***NI **NS *P ***NI ***NI ***Safe ***Ganodermic acid JBA ***NI **NS **P ***NI ***NI ***Safe ***Absorbed: A, Non-inhibitor: NI, Inhibitor: I, Non-substrate: NS, Penetrable: P, High confidence: ***, Medium confidence: ** and Low confidence: *. ADME profile of G. lucidum- derived phytochemicals. Absorbed: A, Non-inhibitor: NI, Inhibitor: I, Non-substrate: NS, Penetrable: P, High confidence: ***, Medium confidence: ** and Low confidence: *. In terms of toxicity, selected phytochemicals were tested for neurotoxicity, hepatotoxicity, carcinogenicity and mutagenicity (Table 3). Among them, no compounds exhibited hERG blockage. Alpha-Terpineol, 3,7-Dimethylocta-1,6-dien-3-ol(linalool), Epoxyganoderiol C, 5,6-Dihydroergosterol, Ganoderiol A and Ganoderol B exhibited no toxicity while the rest 10 compounds showed toxicity in any of the area. Final 5 phytochemicals were then selected for molecular docking. Table 3Toxicity profile of G. lucidum- derived phytochemicals.PhytochemicalsNeurotoxicityHepatotoxicityCarcinogenicityAMES Mutagenesis(+)-EpogymnolactamInactiveInactiveInactiveToxic ***Alpha-TerpineolInactiveInactiveInactiveSafe ***3,7-Dimethylocta-1,6-dien-3-ol(linalool)InactiveInactiveInactiveSafe ***Epoxyganoderiol AInactiveInactiveActive (50%)Safe **Epoxyganoderiol BInactiveInactiveActiveSafe ***Epoxyganoderiol CInactiveInactiveInactiveSafe *5,6-DihydroergosterolInactiveInactiveInactiveSafe ***Ganoderal AActiveInactiveInactiveSafe ***Ganoderal BInactiveInactiveActiveSafe ***Ganoderic aldehyde AInactiveInactiveActiveSafe ***Ganoderic aldehyde TRInactiveInactiveActiveSafe ***Ganoderiol AInactiveInactiveInactiveSafe *Ganoderol BInactiveInactiveInactiveSafe **Lucialdehyde AActiveInactiveInactiveSafe ***Lucidumol BInactiveInactiveActiveSafe **Ganodermic acid JBInactiveInactiveActiveSafe * Toxicity profile of G. lucidum- derived phytochemicals. Prediction of Aβ metal binding sites In this study, the Aβ metal-binding site was targeted as a therapeutic strategy for AD. Metal ions such as copper (Cu), zinc (Zn), and iron (Fe) interact directly with Aβ, promoting its aggregation into neurotoxic plaques and driving the generation of reactive oxygen species (ROS). Targeting these metal-binding sites may inhibit Aβ aggregation, reduce oxidative stress, and restore metal homeostasis, thereby offering potential to slow or prevent AD progression.5, 45, 46 We used Metal Ion-Binding (MIB2) server to predict the metal binding sites of Aβ. The Aβ metal binding site predictions indicate a conserved pocket enriched in acidic (GLU, ASP) and histidine residues that accommodate multiple metal ions with ion- and oxidation state specific preferences. Cu2⁺ binding is dominated by GLU3, HIS6, and GLU11, with additional contribution from GLN15, whereas Cu⁺ involves a broader set including HIS6, ASP7, HIS13, and HIS14. Fe2⁺ shows extensive coordination through GLU3, HIS6, HIS14, GLU11, ARG5, GLN15, and VAL18, while Fe3⁺ binding is more restricted to GLU3, HIS6, ASP7, and HIS14. Zn2⁺ overlaps with these sites, particularly ASP7, GLU11, HIS13, and HIS14 (Table 4). Collectively, these results reinforce the presence of a versatile yet conserved metal-binding environment in Aβ, where acidic (GLU, ASP) and histidine residues orchestrate selective coordination of Cu, Fe, and Zn ions. Subtle variations in residue involvement reflect ion identity and oxidation state, which may underlie differential effects on Aβ aggregation and redox activity. Table 4Predicted metal binding sites of Aβ.Copper (Cu2⁺)Residue NumberAmino AcidScore3GLU2.8496HIS2.84911GLU2.08715GLN2.087Copper (Cu⁺)Residue NumberAmino AcidScore6HIS2.8347ASP2.83411GLU0.81412VAL1.41213HIS2.99414HIS2.994Iron (Fe2⁺)Residue NumberAmino AcidScore3GLU1.7725ARG1.5666HIS1.77211GLU1.56613HIS1.56614HIS2.02115GLN2.02118VAL2.021Iron (Fe3⁺)Residue NumberAmino AcidScore3GLU2.3376HIS2.3377ASP2.59714HIS2.597Zinc (Zn2⁺)Residue NumberAmino AcidScore7ASP2.78911GLU2.32413HIS2.78914HIS2.789 Predicted metal binding sites of Aβ. Molecular docking analysis Molecular docking serves as a critical computational approach for predicting the binding affinities and interaction profiles of potential phytochemical candidates with Aβ. In this study, the docking results reveal that among the selected phytochemicals, 5,6-dihydroergosterol (−7.9 kcal/mol), Epoxyganoderiol C (−7.8 kcal/mol), and Ganoderiol A (−7.7 kcal/mol) exhibited the strongest binding affinities toward Aβ, followed closely by Ganoderol B (−6.9 kcal/mol). In contrast, Alpha-terpineol (−4.6 kcal/mol) and linalool (−4.1 kcal/mol) showed comparatively weaker interactions (Table 5). These findings suggest that triterpenoid compounds, particularly 5,6-dihydroergosterol and Epoxyganoderiol C, may provide greater stability in binding to Aβ, highlighting their potential as promising candidates for modulating amyloid aggregation in AD. The binding conformations of the receptor–ligand complexes are illustrated in Fig. 4(A–D). The corresponding interacting amino acid residues, along with the types of molecular interactions, are presented in Table 6 and visualized in Fig. 5(A–D). Table 5Binding energies of the selected phytochemicals and their target protein (Aβ).ReceptorLigands (Phytochemicals)Binding Energies (Kcal/mol)Amyloid beta (Aβ)Alpha-Terpineol−4.63,7-Dimethylocta-1,6-dien-3-ol(linalool)−4.1Epoxyganoderiol C−7.85,6-Dihydroergosterol−7.9Ganoderiol A−7.7Ganoderol B−6.9 Binding energies of the selected phytochemicals and their target protein (Aβ). Molecular docking: Binding of the selected phytochemicals and Aβ binding sites. A) 5,6-Dihydroergosterol_Aβ; B) Epoxyganoderiol C_Aβ; C) Ganoderiol A_Aβ; D) Ganoderol B_Aβ. Table 6Contact residues and bond types of the selected phytochemicals and their target protein (Aβ).ReceptorLigands (Phytochemicals)Contact residuesBond typesAmyloid beta (Aβ)5,6-DihydroergosterolA:ARG:5Pi-AlkylA:GLU:11Pi-AlkylA:GLU:11Pi-SigmaA:VAL:18AlkylA:PHE:19Pi-AlkylEpoxyganoderiol CA:ARG:5Conventional H-BondA:ARG:5Conventional H-BondGanoderiol AA:HIS:6Conventional H-BondA:ASP:7Carbon-Hydrogen BondA:GLU:11Conventional H-BondA:GLU:11Unfavorable Donor-DonorA:PHE:19Pi-SigmaGanoderol BA:PHE:4Carbon-Hydrogen BondA:GLU:22Carbon-Hydrogen Bond Contact residues and bond types of the selected phytochemicals and their target protein (Aβ). Binding interactions (Bond types) between selected phytochemicals and Aβ binding sites. A) 5,6-Dihydroergosterol_Aβ; B) Epoxyganoderiol C_Aβ; C) Ganoderiol A_Aβ; D) Ganoderol B_Aβ. Various types of interactions are indicated using colored lines: Green lines: Conventional hydrogen bonds, Pale green shading: van der Waals interactions, Purple lines: Pi-sigma interactions, Red lines: Unfavorable donor–donor interactions, other colors indicate specific interaction types (e.g., electrostatic, pi-cation, etc.). Integrating the docking and metal-binding site analyses, the results revealed that Aβ harbors a conserved binding pocket enriched in ARG3, HIS6, ASP7, GLU11, HIS13, HIS14, and GLN15, which contribute to both phytochemical interactions and metal ion coordination. Docking analyses showed that phytochemicals interact with this pocket through hydrogen bonding, hydrophobic interactions, and π-interactions, with Epoxyganoderiol C, 5,6-dihydroergosterol, and Ganoderiol A exhibiting more stable and diverse binding modes compared to others. Metal-binding predictions further indicated that acidic and histidine residues, particularly GLU3, HIS6, HIS13, HIS14, ASP7, and GLU11, coordinate Cu, Fe, and Zn in an oxidation state–dependent manner. The overlap between docking and metal-binding residues suggests that compounds may compete with metal ions for Aβ binding sites, thereby attenuating both Aβ aggregation and metal-induced oxidative stress, which represent two central pathological mechanisms in AD (Fig. 6). Schematic representation of Aβ aggregation and metal-driven oxidative stress, and its modulation by G. lucidum phytochemicals. Top panel: Key Aβ residues (GLU3, ARG5, HIS6, ASP7, GLU11, HIS13, HIS14, GLN15, VAL12, VAL18) coordinate transition metals (Cu2⁺, Fe2⁺/Fe3⁺, Zn2⁺), promoting Aβ aggregation and oxidative stress. Bottom panel: Selected G. lucidum-derived phytochemicals—Ganoderiol A, Epoxyganoderiol C, and 5,6-Dihydroergosterol—interact with these residues, potentially disrupting metal binding, mitigating Aβ aggregation, and reducing metal-driven oxidative stress. Red lines indicate predicted inhibitory interactions of the phytochemicals with key metal-binding residues. Molecular dynamic simulation study Molecular dynamics (MD) simulations were conducted to evaluate the structural stability, conformational flexibility, and dynamic behavior of the protein–ligand complexes under conditions that mimic the physiological environment.47 RMSD analysis (Fig. 7A) showed that all three complexes stabilized after ∼ 10 ns, remaining within an acceptable range (<2.0 Å). The average RMSD values were ∼ 1.2 Å for 5,6-Dihydroergosterol, ∼1.4 Å for Epoxyganoderiol C, and ∼ 1.6 Å for Ganoderiol A, indicating stable conformations for all ligands. RMSF profiles (Fig. 7B) also remained within the acceptable range (<3.0 Å), with Epoxyganoderiol C showing the least flexibility (∼0.8–1.5 Å), followed by 5,6-Dihydroergosterol (∼1.0–2.0 Å), while Ganoderiol A displayed slightly higher fluctuations (∼1.0–2.8 Å) around residues 10–20. These findings confirm that all ligands stabilized the protein backbone without inducing major structural deviations. Molecular dynamics (MD) simulation profiles of protein–ligand complexes over 100 ns. A) Root mean square deviation (RMSD) showing overall structural stability of the complexes; B) Root mean square fluctuation (RMSF) illustrating residue-level flexibility; C) Radius of gyration (Rg) indicating consistent compactness of the complexes; D) Solvent-accessible surface area (SASA) showing solvent exposure levels. The Rg analysis (Fig. 7C) demonstrated stable compactness for all complexes, with average values of ∼ 2.6 Å for Epoxyganoderiol C, ∼2.8 Å for 5,6-Dihydroergosterol, and ∼ 3.0 Å for Ganoderiol A, all of which fall within acceptable limits. Similarly, SASA analysis (Fig. 7D) showed consistent solvent exposure, ranging between ∼ 250–450 Å2 for 5,6-Dihydroergosterol, ∼300–500 Å2 for Epoxyganoderiol C, and ∼ 400–600 Å2 for Ganoderiol A, again within a physiologically acceptable range. Overall, these results demonstrate that all three compounds maintained acceptable structural stability, compactness, and solvent exposure. The protein–ligand interaction analysis was performed to evaluate the nature, strength, and persistence of binding contacts throughout the molecular dynamics (MD) trajectory. In the case of 5,6-Dihydroergosterol_Aβ (Fig. 8A), strong hydrogen bonding was observed primarily with Glu9, showing the highest interaction fraction (∼1.6), along with additional hydrogen bonds and water bridges at residues such as Asp1, Glu7, and Val36. Hydrophobic and ionic contacts were less frequent, indicating that hydrogen bonding dominated the stabilization of this complex. Protein–ligand interaction profiles showing the fractions of hydrogen bonds, hydrophobic contacts, ionic interactions, and water bridges across residues during MD simulations. A) 5,6-Dihydroergosterol_Aβ; B) Epoxyganoderiol C_Aβ; C) Ganoderiol A_Aβ. For Epoxyganoderiol C_Aβ (Fig. 8B), multiple residues contributed to diverse interactions, including hydrogen bonds with residues such as Glu11, Ala12, and Glu22 (interaction fractions ∼ 0.02–0.05), hydrophobic contacts with Val17 and Phe20, and water bridges at residues such as Asp1, Ser26, and Ala29 (∼0.10–0.14). Ganoderiol A_Aβ (Fig. 8C) exhibited broader interaction coverage across residues, with notable hydrogen bonding and water bridge contributions at residues Glu3, Glu7, and Phe19 (interaction fractions ∼ 0.20–0.35). Hydrophobic interactions also played a stabilizing role, particularly at Phe4, Val17, and Val36. Collectively, these results confirm that all three ligands formed stable, persistent, and complementary interactions within the Aβ binding pocket. Calculation of binding free energy (MMGBSA) The MM/GBSA binding free energy (ΔG_bind) analysis confirmed that all three ligands formed thermodynamically stable complexes with Aβ, indicating their suitability as potential binders. The total binding free energies were –71.66 kcal/mol for 5,6-Dihydroergosterol, –56.42 kcal/mol for Epoxyganoderiol C, and –45.45 kcal/mol for Ganoderiol A (Table 7), all of which fall within the acceptable range for stable binding. Table 7The results of binding free energy calculations for 3 G. lucidum compounds against Aβ.ComplexΔGbindΔGbind H-bondΔGbind LipoΔGbind vdW5,6-Dihydroergosterol_Aβ−71.66−1.62−27.63−55.27Epoxyganoderiol C_Aβ−56.42−1.66−28.12−46.44Ganoderiol A_Aβ−45.45−1.55−19.42−30.22 The results of binding free energy calculations for 3 G. lucidum compounds against Aβ. Decomposition of binding energies revealed that van der Waals and lipophilic interactions were the predominant stabilizing forces, with contributions of –55.27 and –27.63 kcal/mol for 5,6-Dihydroergosterol, –46.44 and –28.12 kcal/mol for Epoxyganoderiol C, and –30.22 and –19.42 kcal/mol for Ganoderiol A, respectively. Hydrogen bonds, though smaller in contribution (–1.55 to –1.62 kcal/mol), further enhanced stability (Table 7). Taken together, these results demonstrate that all three ligands are suitable binding candidates for Aβ. Discussion In these studies, we aimed to explore the therapeutic potential of G. lucidum phytochemicals in the context of AD, in a C. elegans AD models. We also employed a comprehensive approach that combined computational drug-likeness screening, ADME/toxicity profiling, molecular docking, and dynamic simulations to identify G. lucidum derived phytochemical which are attributed as an inhibitor for the Aβ aggregation as well as AD progression. The nematode C. elegans has emerged as a powerful in vivo model for studying AD pathogenesis and screening neuroprotective compounds due to its highly conserved neuronal pathways, short lifespan, transparent body, and the availability of transgenic strains expressing human Aβ.48, 49 Notably, C. elegans lacks endogenous Aβ production, allowing direct assessment of Aβ toxicity without confounding background interference. These features make it a cost-effective and genetically tractable platform for evaluating anti-AD interventions. After that, we utilized C. elegans AD models to assess the neuroprotective effects of G. lucidum methanolic extract. Our findings demonstrated that the extract significantly delayed Aβ-induced paralysis and improved stress resistance under paraquat-induced oxidative conditions. These results suggest that G. lucidum confers protective effects by mitigating oxidative stress and reducing Aβ-related neurotoxicity. Accumulating evidence suggest that observed benefits may be attributed to its rich profile of antioxidant triterpenoids (Epoxyganoderiol C and Ganoderiol A) and sterol (5,6-Dihydroergosterol), known for their ROS-scavenging and neuroprotective properties. Thus, G. lucidum represents a promising natural candidate for the development of multi-target therapeutics against AD. Neurodegenerative disorders, including AD, are thought to be aggravated by oxidative stress. This condition arises from the misfolded proteins accumulation, such as Aβ, which promotes excessive generation of ROS.50 The resulting oxidative imbalance contributes to neuronal damage, ultimately leading to cell degeneration and death. Our results showed that, 125 μg/ml G. lucidum extract possess highest antioxidant activity (96%) assessed by DPPH assay. In N2 strain, 0.5 mg/ml G. lucidum extract exhibited significant protective effect against paraquate oxidative stress. As the concentration increased by three-fold the protective effect was less than 0.5 mg/ml. Previous research has demonstrated that high doses of the extracts can exert detrimental effects, while lower doses fail to provide significant protective benefits. This observation may be attributed to the beneficial actions of the compounds through a dose-dependent adaptive response mechanism known as hormesis.51, 52, 53 G. lucidum extract provide a protective effect to worm by delaying Aβ-induced paralysis. From the paralysis assay in CL4176 strain shows that, 0.5 mg/ml G. lucidum extract provide the best protective effect where 35% worm were not paralyzed compared to control (15%) after 60 hrs. Thus, it is possible that the reduced Aβ induced paralysis in C. elegans treated with the G. lucidum extracts may result from the actions of triterpenoids, sterols and phenolic compounds in the extracts. Methanolic extracts of G. lucidum are rich in bioactive compounds including, triterpenoids (Epoxyganoderiol C and Ganoderiol A) and sterol (5,6-Dihydroergosterol), which have demonstrated the ability to scavenge ROS and modulate pathways involved in neuronal survival and inflammation.54 Initial drug-likeness screening based on Lipinski’s rule of five55 eliminated compounds with poor oral bioavailability, retaining 213 compounds with no more than one violation. Key parameters such as molecular weight (MW ≤ 500 Da), hydrogen bond donors/acceptors, TPSA (<140 Å2), and iLogP (≤5) are known to predict membrane permeability and gastrointestinal absorption.28, 56 Among these, 15 compounds showed favorable pharmacokinetic profiles, with high intestinal absorption, good BBB permeability, and no significant interaction with CYP2D6 or CYP3A4 enzymes, key mediators of hepatic drug metabolism.57 Importantly, none of the selected compounds were predicted as P-gp substrates, minimizing the risk of efflux-mediated CNS exclusion.58 However, certain compounds like Epoxyganoderiol A–C and Ganoderiol A exhibited P-gp inhibitory activity, which may affect multidrug resistance but could potentially enhance CNS uptake in co-therapies. Absence of hERG inhibition across all compounds suggests a low risk of cardiotoxicity, a common late-stage failure factor in drug development.59 Toxicity prediction using pkCSM and admetSAR indicated that six compounds, including Alpha-Terpineol, Linalool, Epoxyganoderiol C, 5,6-Dihydroergosterol, Ganoderiol A, and Ganoderol B, exhibited no neurotoxicity, hepatotoxicity, carcinogenicity, or mutagenicity, justifying their selection for molecular docking analysis. In C. elegans AD models, transition metals such as copper (Cu), iron (Fe), and zinc (Zn) play a pivotal role in modulating amyloid-β (Aβ) aggregation and oxidative stress.60 Cu and Fe bind strongly to histidine residues within Aβ, accelerating oligomerization and fibril formation, while their redox cycling (Cu2⁺/Cu⁺, Fe3⁺/Fe2⁺) drives Fenton-like reactions that elevate reactive oxygen species and neuronal damage.61, 62 In contrast, Zn promotes rapid Aβ aggregation through coordination with histidine-rich regions but, being redox-inactive, mainly contributes to dense plaque formation and synaptic dysregulation.63 In C. elegans, dysregulated Cu, Fe, and Zn accelerate paralysis, increase plaque burden, and enhance oxidative stress, whereas chelation or antioxidant phytochemicals mitigate these effects.64, 65, 66 Collectively, these findings highlight that Cu and Fe predominantly exacerbate Aβ toxicity through redox imbalance, while Zn enhances structural aggregation, together forming a pathological triad that underscores the therapeutic relevance of targeting metal dyshomeostasis in AD. Molecular docking is a valuable computational tool for predicting the binding affinities and interaction profiles of potential phytochemicals with Aβ. In the present study, docking analysis indicated that 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A exhibited the highest binding affinities toward Aβ, whereas Ganoderol B displayed slightly lower affinity. In contrast, Alpha-terpineol and linalool demonstrated comparatively weaker interactions (Table 5). These results suggest that 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A, may confer greater stability in binding to Aβ, supporting their potential as promising candidates for modulating amyloid aggregation in AD. MD simulations were carried out to validate the stability and dynamic properties of the protein–ligand complexes under near-physiological conditions. The RMSD values of all three complexes stabilized within 100 ns and remained below 2.0 Å, indicating conformational stability throughout the simulation, which is consistent with earlier reports suggesting RMSD < 2.0 Å as an indicator of stable complexes.67, 68 RMSF profiles demonstrated limited residue-level fluctuations (<3.0 Å), confirming that ligand binding did not cause significant structural perturbations, in agreement with previous studies where low RMSF values reflect ligand-induced stabilization.69 Similarly, the Rg and SASA analyses showed that all three ligands maintained compact protein structures with acceptable solvent accessibility, further confirming complex stability.70, 71 The interaction fraction profiles highlighted that all compounds established stable hydrogen bonds, hydrophobic contacts, and water bridges with key residues of Aβ. 5,6-Dihydroergosterol_Aβ was dominated by strong hydrogen bonding, whereas Epoxyganoderiol C_Aβ and Ganoderiol A_Aβ demonstrated more balanced contributions from hydrophobic and water-mediated interactions. This aligns with previous findings that persistent hydrogen bonding and hydrophobic contacts are critical for stabilizing Aβ–ligand complexes.72, 73 Furthermore, MM/GBSA free energy calculations revealed favorable ΔG_bind values for all ligands (–43.35 to –76.66 kcal/mol), within the range reported for stable Aβ binders.42, 74 Decomposition analysis confirmed that van der Waals and lipophilic interactions were the primary driving forces of binding, with hydrogen bonding providing additional stabilization, consistent with previous computational analyses.42, 75 Collectively, these findings indicate that all three compounds—5,6-Dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A—are suitable candidates for Aβ targeting, with 5,6-Dihydroergosterol showing the most favorable stability and binding affinity. By integrating docking and metal-binding site analyses, our study highlights that Aβ contains a conserved binding pocket enriched in ARG3, HIS6, ASP7, GLU11, HIS13, HIS14, and GLN15, which are central to both phytochemical binding and metal ion coordination. Notably, 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A established stronger and more diverse interactions than others, indicating their greater stabilizing potential. The predicted coordination of Cu, Fe, and Zn by GLU3, HIS6, HIS13, HIS14, ASP7, and GLU11 reflects the critical role of acidic and histidine residues in metal-induced Aβ aggregation. The overlap between phytochemical docking and metal-binding residues suggests a functional convergence, whereby phytochemicals may competitively interfere with metal binding, thereby destabilizing the Aβ–metal complex. This dual-targeting capacity underscores the therapeutic relevance of selected G. lucidum–derived compounds (5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A) in mitigating both Aβ aggregation and metal-driven oxidative stress, addressing two central pathological mechanisms in AD. Overall, 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A emerged as promising drug-like candidates with favorable ADME-toxicity profiles and high binding affinity for Aβ. These findings support previous reports on the neuroprotective and antioxidant potential of Ganoderma lucidum triterpenoids (Epoxyganoderiol C and Ganoderiol A) and sterol (5,6-Dihydroergosterol),76, 77 and offer novel insights into their possible anti-Alzheimer’s applications. The proposed mechanism underlying the neuroprotective effects of Ganoderma lucidum-derived compounds in mitigating Alzheimer’s-like pathology, along with potential therapeutic insights from this study, is illustrated in Fig. 9. Schematic representation of the neuroprotective effects of G. lucidum on Alzheimer’s-like pathology in C. elegans AD models. The left panel illustrates the normal pathological process, where Aβ accumulation, enhanced by metal ions (Fe3⁺, Fe2⁺, Cu2⁺, Zn2⁺), leads to Aβ aggregation, increased ROS, and paralysis. The right panel shows the effects of G. lucidum compounds (Epoxyganoderiol C, Ganoderiol A, 5,6-Dihydroergosterol), which bind to Aβ at its metal-binding site, preventing metal ion interaction. This results in reduced Aβ aggregation, lower ROS levels, and alleviated paralysis in C. elegans AD models. This study has several limitations. The antioxidant activity was assessed only using the DPPH assay, without complementary biochemical or cell-based methods (e.g., ABTS, FRAP, ORAC, or cellular ROS), which may limit a comprehensive evaluation. Key stress-response pathways, including DAF-16/FOXO, SKN-1/Nrf2, and HSF-1 signaling, were not explored, restricting mechanistic interpretation of the observed neuroprotective effects. In addition, detailed phytochemical characterization of G. lucidum extract (e.g., HPLC/LC–MS or GC–MS) was not conducted, limiting direct experimental validation of bioactive compounds predicted through in silico approaches. While ADMET analysis provided preliminary insights into pharmacokinetic and safety profiles, these findings lack experimental validation through in vitro and in vivo studies. Furthermore, MD simulations were limited to 100 ns, which, although sufficient for initial stability assessment, may not fully capture long-term conformational dynamics (200 ns). Future studies addressing these limitations will strengthen the reliability and translational relevance of the findings. Conclusion In conclusion, this study demonstrates that G. lucidum possesses significant therapeutic potential against AD–like pathology through a combined in vivo and in silico strategy. Using C. elegans AD models, the methanolic extract of G. lucidum effectively delayed Aβ-induced paralysis and enhanced resistance to oxidative stress, highlighting its neuroprotective and antioxidant capacity. These effects were most pronounced at optimal low doses, supporting a hormetic mechanism of action. Comprehensive computational analyses further identified 5,6-dihydroergosterol, Epoxyganoderiol C, and Ganoderiol A as promising drug-like candidates with favorable ADME–toxicity profiles, strong blood–brain barrier permeability, and minimal safety liabilities. Molecular docking, dynamics simulations, and MM/GBSA calculations revealed stable and energetically favorable interactions of these compounds with Aβ, particularly at residues critical for metal ion coordination. The overlap between phytochemical-binding and metal-binding sites suggests a dual mechanism involving inhibition of Aβ aggregation and attenuation of metal-induced oxidative stress. Collectively, these findings provide mechanistic insight into the anti-Alzheimer’s potential of G. lucidum–derived triterpenoids and sterols and support their further validation through in vitro and mammalian in vivo studies as multi-target therapeutic candidates for AD. CRediT authorship contribution statement Mojnu Mia: Writing – original draft, Validation, Methodology, Formal analysis, Conceptualization. Amit Dutta: Writing – review & editing, Writing – original draft, Visualization, Methodology, Formal analysis, Data curation, Conceptualization. Md. Mainuddin Hossain: Writing – review & editing, Writing – original draft, Visualization, Software, Methodology, Formal analysis, Data curation. Juthi Adhikari: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation. Md. Masuder Rahman: Writing – review & editing, Validation, Methodology, Investigation, Conceptualization. Abu Zaffar Shibly: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Conceptualization. Funding There is no funding for this research. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Abu zaffar shibly reports a relationship with Mawlana Bhashani Science and Technology University that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgment None Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.jgeb.2026.100706. Contributor Information Md. Masuder Rahman, Email: masud@mbstu.ac.bd. Abu Zaffar Shibly, Email: zaffarshibly1987@gmail.com. Supplementary data The following are the Supplementary data to this article: Supplementary Data 1 Data availability Data included in article/supp. material/referenced in article. References Associated Data Supplementary Materials Supplementary Data 1 Data Availability Statement Data included in article/supp. material/referenced in article.